Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Dyslipidemia | Research article

Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism

Authors: Selvihan Beysel, Mustafa Caliskan, Muhammed Kizilgul, Mahmut Apaydin, Seyfullah Kan, Mustafa Ozbek, Erman Cakal

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Parathyroidectomy has ameliorated cardiovascular risk factors in patients with hypercalcemic primary hyperparathyroidism (PHPT), but the effect of parathyroidectomy on normocalcemic PHPT is not exactly known. This case-controlled study aimed to investigate the effect of parathyroidectomy on cardiovascular risk factors in patients with normocalcemic and hypercalcemic PHPT.

Methods

Subjects with normocalcemic PHPT (n = 35), age- and sex-matched hypercalcemic PHPT (n = 60) and age- and sex-matched control (n = 60) were included. Cardiometabolic disorders were investigated with traditional cardiometabolic risk factors and the Framingham cardiovascular risk score (CRS) before and 6 months after parathyroidectomy.

Results

Diabetes, dyslipidemia, hypertension, obesity, insulin resistance, osteoporosis, having fractures were similarly increased in the hypercalcemic and normocalcemic PHPT groups (p > 0.05) compared with the controls (p < 0.05). Blood pressures, glucose metabolism (glucose, insulin, HOMA-IR) and lipid profiles were similarly increased in the PHPT groups (p > 0.05) compared with the controls (p < 0.05). After parathyroidectomy, blood pressures, serum total cholesterol, and HOMA-IR were decreased in both PHPT groups (p < 0.05). CRS was lower in the controls (5.74 ± 3.24, p < 0.05). After parathyroidectomy, CRS was decreased in the normocalcemic (11.98 ± 10.11 vs. 7.37 ± 4.48) and hypercalcemic (14.62 ± 11.06 vs. 8.05 ± 7.72) PHPT groups. Increased blood pressures were independent predictors of serum iPTH.

Conclusion

The normocalcemic and hypercalcemic PHPT groups had similarly increased cardiovascular risk factors, even independently of serum calcium. Parathyroidectomy ameliorated the increased cardiovascular risk factors in both normocalcemic and hypercalcemic PHPT.
Literature
1.
go back to reference Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3580–94.CrossRef Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3580–94.CrossRef
2.
go back to reference Díaz-Soto G, Julián MT, Puig-Domingo M. Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention. Hormones (Athens). 2012;11:390–6.CrossRef Díaz-Soto G, Julián MT, Puig-Domingo M. Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention. Hormones (Athens). 2012;11:390–6.CrossRef
3.
go back to reference Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2010;54:106–9.CrossRef Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2010;54:106–9.CrossRef
4.
go back to reference Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.CrossRef Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.CrossRef
5.
go back to reference Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom Off J Int Soc Clin Densitom. 2013;16:33–9.CrossRef Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom Off J Int Soc Clin Densitom. 2013;16:33–9.CrossRef
6.
go back to reference Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Investig. 2009;32:317–21.CrossRef Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Investig. 2009;32:317–21.CrossRef
7.
go back to reference Tassone F, Maccario M, Gianotti L, Baffoni C, Pellegrino M, et al. Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine. 2013;44:812–4.CrossRef Tassone F, Maccario M, Gianotti L, Baffoni C, Pellegrino M, et al. Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine. 2013;44:812–4.CrossRef
8.
go back to reference Farahnak P, Lärfars G, Sten-Linder M, Nilsson I-L. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab. 2011;96:2112–8.CrossRef Farahnak P, Lärfars G, Sten-Linder M, Nilsson I-L. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab. 2011;96:2112–8.CrossRef
9.
go back to reference Hagström E, Lundgren E, Lithell H, Berglund L, Ljunghall S, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol. 2002;56:253–60.CrossRef Hagström E, Lundgren E, Lithell H, Berglund L, Ljunghall S, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol. 2002;56:253–60.CrossRef
10.
go back to reference Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011;17:584–90. Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011;17:584–90.
11.
go back to reference Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47:581–9.CrossRef Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47:581–9.CrossRef
12.
go back to reference Ahlström T, Hagström E, Larsson A, Rudberg C, Lind L, et al. Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol. 2009;71:673–8.CrossRef Ahlström T, Hagström E, Larsson A, Rudberg C, Lind L, et al. Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol. 2009;71:673–8.CrossRef
13.
go back to reference Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34:1567–73.CrossRef Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34:1567–73.CrossRef
14.
go back to reference Jorde R, Bonaa KH, Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol Eur Fed Endocr Soc. 1999;141:350–7.CrossRef Jorde R, Bonaa KH, Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol Eur Fed Endocr Soc. 1999;141:350–7.CrossRef
15.
go back to reference Reid IR, Gamble GD, Bolland MJ. Circulating calcium concentrations, vascular disease and mortality: a systematic review. J Intern Med. 2016;279:524–40.CrossRef Reid IR, Gamble GD, Bolland MJ. Circulating calcium concentrations, vascular disease and mortality: a systematic review. J Intern Med. 2016;279:524–40.CrossRef
16.
go back to reference Tordjman KM, Yaron M, Izkhakov E, Osher E, Shenkerman G, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol Eur Fed Endocr Soc. 2010;162:925–33.CrossRef Tordjman KM, Yaron M, Izkhakov E, Osher E, Shenkerman G, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol Eur Fed Endocr Soc. 2010;162:925–33.CrossRef
17.
go back to reference Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457–64.CrossRef Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457–64.CrossRef
19.
go back to reference Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90:1525–30.CrossRef Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90:1525–30.CrossRef
20.
go back to reference Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø study. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol. 2004;11:69–74. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø study. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol. 2004;11:69–74.
21.
go back to reference Reis JP, von Mühlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007;30:1549–55.CrossRef Reis JP, von Mühlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007;30:1549–55.CrossRef
22.
go back to reference Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Investig. 2012;35:548–52. Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Investig. 2012;35:548–52.
23.
go back to reference Tassone F, Gianotti L, Baffoni C, Cesario F, Magro G, et al. Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J Endocrinol Investig. 2012;35:841–6. Tassone F, Gianotti L, Baffoni C, Cesario F, Magro G, et al. Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J Endocrinol Investig. 2012;35:841–6.
24.
go back to reference Khaleeli AA, Johnson JN, Taylor WH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev. 2007;23:43–8.CrossRef Khaleeli AA, Johnson JN, Taylor WH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev. 2007;23:43–8.CrossRef
25.
go back to reference Nilsson I-L, Aberg J, Rastad J, Lind L. Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery. 2005;137:632–8.CrossRef Nilsson I-L, Aberg J, Rastad J, Lind L. Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery. 2005;137:632–8.CrossRef
26.
go back to reference Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63:111–8.CrossRef Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63:111–8.CrossRef
27.
go back to reference Temizkan S, Kocak O, Aydin K, Ozderya A, Arslan G, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21:23–9. Temizkan S, Kocak O, Aydin K, Ozderya A, Arslan G, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21:23–9.
28.
go back to reference Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol Eur Fed Endocr Soc. 2006;155:33–9.CrossRef Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol Eur Fed Endocr Soc. 2006;155:33–9.CrossRef
29.
go back to reference Chen G, Xue Y, Zhang Q, Xue T, Yao J, et al. Is Normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab. 2015;100:2420–4.CrossRef Chen G, Xue Y, Zhang Q, Xue T, Yao J, et al. Is Normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab. 2015;100:2420–4.CrossRef
30.
go back to reference Van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165(655–664):664.e1–5. Van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165(655–664):664.e1–5.
31.
go back to reference Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765–71.CrossRef Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765–71.CrossRef
32.
go back to reference Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens. 2005;23:1639–44.CrossRef Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens. 2005;23:1639–44.CrossRef
33.
go back to reference Lee DM, Rutter MK, O’Neill TW, Boonen S, Vanderschueren D, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol Eur Fed Endocr Soc. 2009;161:947–54.CrossRef Lee DM, Rutter MK, O’Neill TW, Boonen S, Vanderschueren D, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol Eur Fed Endocr Soc. 2009;161:947–54.CrossRef
34.
go back to reference Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJH, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med. 2007;261:558–65.CrossRef Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJH, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med. 2007;261:558–65.CrossRef
35.
go back to reference Hjelmesaeth J, Hofsø D, Aasheim ET, Jenssen T, Moan J, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol. 2009;8:7.CrossRef Hjelmesaeth J, Hofsø D, Aasheim ET, Jenssen T, Moan J, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol. 2009;8:7.CrossRef
36.
go back to reference Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63:20–31.CrossRef Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63:20–31.CrossRef
37.
go back to reference Potthoff SA, Janus A, Hoch H, Frahnert M, Tossios P, et al. PTH-receptors regulate norepinephrine release in human heart and kidney. Regul Pept. 2011;171:35–42.CrossRef Potthoff SA, Janus A, Hoch H, Frahnert M, Tossios P, et al. PTH-receptors regulate norepinephrine release in human heart and kidney. Regul Pept. 2011;171:35–42.CrossRef
38.
go back to reference Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, et al. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 2012;126:1031–9.CrossRef Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, et al. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 2012;126:1031–9.CrossRef
39.
go back to reference Almqvist EG, Bondeson A-G, Bondeson L, Svensson J. Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism. Scand J Clin Lab Invest. 2011;71:139–44.CrossRef Almqvist EG, Bondeson A-G, Bondeson L, Svensson J. Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism. Scand J Clin Lab Invest. 2011;71:139–44.CrossRef
40.
go back to reference Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:132–7.CrossRef Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:132–7.CrossRef
41.
go back to reference Delfini E, Petramala L, Caliumi C, Cotesta D, De Toma G, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56:30–6.CrossRef Delfini E, Petramala L, Caliumi C, Cotesta D, De Toma G, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56:30–6.CrossRef
42.
go back to reference Sukumar D, Partridge NC, Wang X, Shapses SA. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab. 2011;96:1852–8.CrossRef Sukumar D, Partridge NC, Wang X, Shapses SA. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab. 2011;96:1852–8.CrossRef
Metadata
Title
Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism
Authors
Selvihan Beysel
Mustafa Caliskan
Muhammed Kizilgul
Mahmut Apaydin
Seyfullah Kan
Mustafa Ozbek
Erman Cakal
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1093-4

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue